Literature DB >> 29437771

Hepatotoxicity Associated With Vismodegib.

Prabhjot S Bedi1, Manoj P Rai2, Nishant Tageja3, Heather Laird-Fick4.   

Abstract

An 82-year-old Caucasian woman with a history of basal cell carcinoma on vismodegib presented with nausea, vomiting and intermittent abdominal pain. Laboratory results were remarkable for the elevation of liver enzymes. Endoscopic retrograde cholangiopancreatography and percutaneous transhepatic cholangiogram (PTC) did not show evidence of intrahepatic or extrahepatic obstruction of the biliary tract. During PTC external biliary catheter was placed; however, bilirubin continued to rise. Further, laboratory work-up and imaging studies ruled out other possible aetiologies for hepatotoxicity such as infections, autoimmune hepatitis and other drugs known to be hepatotoxic thus leaving vismodegib the most likely cause of hepatotoxicity. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  liver disease; oncology; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2018        PMID: 29437771      PMCID: PMC5836615          DOI: 10.1136/bcr-2017-222969

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

Review 1.  Drug-related hepatotoxicity.

Authors:  Victor J Navarro; John R Senior
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

2.  Vismodegib-associated hepatotoxicity: a potential side effect detected in postmarketing surveillance.

Authors:  Daniel J Ventarola; David I Silverstein
Journal:  J Am Acad Dermatol       Date:  2014-08       Impact factor: 11.527

Review 3.  Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Authors:  Amber E Proctor; Lisa A Thompson; Cindy L O'Bryant
Journal:  Ann Pharmacother       Date:  2013-10-15       Impact factor: 3.154

Review 4.  Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.

Authors:  Frank Cirrone; Christy S Harris
Journal:  Clin Ther       Date:  2012-10-01       Impact factor: 3.393

Review 5.  Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.

Authors:  Mark M Ash; Puneet S Jolly
Journal:  Int J Dermatol       Date:  2014-07-11       Impact factor: 2.736

Review 6.  Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.

Authors:  Tomas G Lyons; Grainne M O'Kane; Catherine M Kelly
Journal:  Expert Opin Drug Saf       Date:  2014-08       Impact factor: 4.250

7.  Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project.

Authors:  Beatrice J Edwards; Dennis W Raisch; Smita S Saraykar; Ming Sun; Josh A Hammel; Hai T Tran; Nathaniel Wehr; Rasha Arabyat; Dennis P West
Journal:  Drugs R D       Date:  2017-03

8.  The dawn of hedgehog inhibitors: Vismodegib.

Authors:  Selvarajan Sandhiya; George Melvin; Srinivasamurthy Suresh Kumar; Steven Aibor Dkhar
Journal:  J Pharmacol Pharmacother       Date:  2013-01

9.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Authors:  Aleksandar Sekulic; Michael R Migden; Nicole Basset-Seguin; Claus Garbe; Anja Gesierich; Christopher D Lao; Chris Miller; Laurent Mortier; Dedee F Murrell; Omid Hamid; Jorge F Quevedo; Jeannie Hou; Edward McKenna; Natalie Dimier; Sarah Williams; Dirk Schadendorf; Axel Hauschild
Journal:  BMC Cancer       Date:  2017-05-16       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.